HALOZYME THERAPEUTICS, INC.

Lobbying Spend

—

Filings

Firms Hired

Active Period

2005–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	4	1
2020	—	4	1
2019	—	3	1
2007	—	2	1
2006	—	1	1
2005	—	3	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
FORBES-TATE	—	30
FOLEY & LARDNER LLP	—	6

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	23
SENATE	23
Centers For Medicare and Medicaid Services (CMS)	14
Health & Human Services, Dept of (HHS)	14
Food & Drug Administration (FDA)	2

Most frequently reported lobbying issues

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 5376117th Congress

Inflation Reduction Act of 2022

2023 · second_quarter · Firm: FORBES-TATE

Cited source text and reported amounts

Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).

Client expense: — · Firm income: $20,000

Matched citations: H.R. 5376

H.R. 925116th Congress

The Heroes Act

2020 · fourth_quarter · Firm: FORBES-TATE

Cited source text and reported amounts

Issues related to H.R. 925 - The Heroes Act.

Client expense: — · Firm income: —

Matched citations: H.R. 925

H.R. 925116th Congress

The Heroes Act

2020 · third_quarter · Firm: FORBES-TATE

Cited source text and reported amounts

Issues related to H.R. 925 - The Heroes Act.

Client expense: — · Firm income: —

Matched citations: H.R. 925

HALOZYME THERAPEUTICS, INC. — Lobbying Disclosure | Poliscope